Hjem › Ikke-småcellet lungekreft › Utah › Salt Lake City
Kliniske studier for Ikke-småcellet lungekreft i Salt Lake City, UT
31 studier for Ikke-småcellet lungekreft søker deltakere på steder i og rundt Salt Lake City (innen ca. 30 miles). Åpne et studie for å se hvem som kan delta og hvordan du kontakter studieteamet.
Offisiell studietekst (engelsk)
Rekrutterer til et studie her? Få det fremtredende øverst på siden – $99 i 30 dager →
Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations
RekruttererFase 1/2
- Huntsman Cancer Institute /ID# 271686, Salt Lake City
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
RekruttererFase 1
- University of Utah - Huntsman Cancer Institute, Salt Lake City
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
RekruttererFase 3
- Utah Cancer Specialists, Salt Lake City
- Huntsman Cancer Institute, Salt Lake City
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
RekruttererFase 3
- Huntsman Cancer Institute ( Site 0042), Salt Lake City
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
RekruttererFase 3
- Huntsman Cancer Institute, University of Utah, Salt Lake City
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
RekruttererFase 2
- Huntsman Cancer Institute, Salt Lake City
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
RekruttererFase 3
- Local Institution - 0302, Salt Lake City
Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer
RekruttererFase 2/3
- Utah Cancer Specialists, Salt Lake City
Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
RekruttererFase 1/2
- University of Utah - Huntsman Cancer Institute, Salt Lake City
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
RekruttererFase 3
- Clinical Study Site, Salt Lake City
A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors
RekruttererFase 1
- Huntsman Cancer Institute, Salt Lake City
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
RekruttererObservasjonsstudie
- Utah Cancer Specialists, Salt Lake City
Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer
RekruttererFase 1
- Huntsman Cancer Institute, Salt Lake City
First-In-Human Study of STX-721/PFL-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR or HER2 Exon 20 Insertion Mutations
RekruttererFase 1/2
- University of Utah - Huntsman Cancer Institute - PPDS, Salt Lake City
MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors
RekruttererFase 1
- Huntsman Cancer Institute, Salt Lake City
A Phase 1 Study of LNCB74 in Advanced Solid Tumors
RekruttererFase 1
- Intermountain/LDS Hospital Ph 1 Research Program, Salt Lake City
Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial
RekruttererFase 3
- Huntsman Cancer Institute/University of Utah, Salt Lake City
A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors
RekruttererFase 1
- START Mountain Region, Salt Lake City
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
RekruttererFase 2
- Huntsman Cancer Institute/University of Utah, Salt Lake City
BBO-11818 in Adult Subjects With KRAS Mutant Cancer
RekruttererFase 1
- Huntsman Cancer Institute, Salt Lake City
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
RekruttererFase 1/2
- Huntsman Cancer Institute, Salt Lake City
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)
RekruttererFase 2
- Huntsman Cancer Institute/University of Utah, Salt Lake City
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
RekruttererFase 2/3
- Huntsman Cancer Institute/University of Utah, Salt Lake City
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
RekruttererFase 2
- Huntsman Cancer Institute/University of Utah, Salt Lake City
Machine Learning Approaches to Personalized Therapy for Advanced Non-small Cell Lung Cancer With Real-World Data
RekruttererObservasjonsstudie
- Huntsman Cancer Institute at the University of Utah, Salt Lake City
Comparative Effectiveness Trial of Two Supportive Cancer Care Delivery Models for Adults With Cancer
Rekrutterer
- George E. Wahlen Department of Veterans Affairs Medical Center, Salt Lake City
A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
RekruttererFase 1/2
- Huntsman Cancer Institute, Salt Lake City
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
RekruttererFase 1/2
- University of Utah, Huntsman Cancer Institute, Salt Lake City
PILOT for The Precision Exercise Regimen for Cancer Care (PERCC) Study
Rekrutterer
- Huntsman Cancer Institute, Salt Lake City
VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
RekruttererFase 1/2
- Utah Cancer Specialists (site 203), Salt Lake City
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
RekruttererObservasjonsstudie
- Massive Bio SYNERGY-AI site, Salt Lake City
Ikke-småcellet lungekreft-studier i andre byer
- Houston, TX145 studier
- New York City, NY121 studier
- Arlington, VA104 studier
- Nashville, TN97 studier
- Boston, MA90 studier
- Los Angeles, CA87 studier
- St. Louis, MO73 studier
- Chicago, IL61 studier
- Baltimore, MD60 studier
- San Antonio, TX59 studier
- Columbus, OH57 studier
- Washington, DC55 studier
Andre studier i Salt Lake City
- Kreft (alle typer)27 studier
- Brystkreft27 studier
- Kolorektal kreft22 studier
- Lungekreft21 studier
- Melanom21 studier
- Multipelt myelom21 studier
- Metastatisk kreft20 studier
- Eggstokkreft19 studier
- Fedme18 studier
- Akut myelogen leukemi17 studier
- Hjertesvikt17 studier
- Prostatakreft15 studier
Fra ClinicalTrials.gov, data hentet 6. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.